Author

B. Seeliger

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Organism:rat· 1

Frequent Co-Authors

A. Prasse· 2 shared A. Birnhuber· 1 shared A. Biswas· 1 shared A. Foti· 1 shared A. Zychlinsky· 1 shared A.-S. Schultz· 1 shared C. Jawale· 1 shared D. Humme· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Prasse

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Tyrosine halogenation converts α-defensins into potent immunomodulators

A. Foti, R. Hurwitz, K. Textoris-Taube, M. Muelleder, A. Biswas, P. Fahjen, M. Winkler, U. Abu Abed, D. Humme, S. Thee, A. Prasse, B. Seeliger, M. Ralser, A. Zychlinsky

The paper identifies that tyrosine halogenation of α-defensins by hypohalous acids converts them into immunomodulatory mediators, revealing a novel oxidative mechanism in neutrophil function.

bioRxiv · Nov 1, 2023 · PreprintImmunology

Altered fibrin clot structure contributes to thrombosis risk in severe COVID-19

M. Wygrecka, A. Birnhuber, B. Seeliger, L. Michalick, O. Pak, A.-S. Schultz, F. Schramm, M. Zacharias, G. Gorkiewicz, S. David, T. Welte, J. J. Schmidt, N. Weissmann, R. T. Schermuly, G. Barreto, , K. T. Preissner

The paper shows that altered fibrin clot structure in severe COVID-19 patients contributes to thrombosis risk by forming compact, fibrinolysis-resistant clots.

bioRxiv · Sep 17, 2021Biochemistry

High CXCL6 drives matrix expression and correlate with markers of poor outcome in IPF

H. Bahudhanapati, J. Tan, R.-M. Apel, B. Seeliger, X. Li, T.-Y. Chen, D. Sullivan, J. Sembrat, M. Rojas, E. Valenzi, R. A. Lafyatis, C. Jawale, P. Biswas, J. Tedrow, T. S. Adams, , D. J. Kass

This study identifies CXCL6 as a pro-fibrotic factor in IPF, showing it reduces cAMP, increases collagen and -SMA, and correlates with poor patient survival.

bioRxiv · Jun 22, 2021 · PreprintCell Biology